Microdosing involves taking sub-perceptual doses of psychedelic substances, typically 5 to 10% of a full dose of psilocybin or LSD, on a recurring schedule. Despite widespread claims of benefits for creativity, mood, focus, and productivity, the scientific evidence is limited and largely based on self-report surveys rather than controlled trials. The few double-blind, placebo-controlled studies completed to date have shown that most perceived benefits of microdosing are indistinguishable from placebo effects. Meanwhile, real risks exist: serotonergic cardiac valvulopathy from chronic 5-HT2B receptor activation, interactions with psychiatric medications, legal consequences, and unregulated product quality.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab
“Microdosing represents an interesting intersection of genuine pharmacological research and unsubstantiated health claims,” says Dr. Ponlawat Pitsuwan. “At Phuket Island Rehab, we see patients who have adopted microdosing regimens as alternatives to evidence-based psychiatric treatment, sometimes discontinuing prescribed medications in favour of unregulated psilocybin or LSD. While therapeutic psychedelic research is a legitimate and promising field, current evidence does not support unsupervised microdosing as a replacement for established treatments.”
What Microdosing Is and How It Differs from Therapeutic Use
Microdosing typically involves taking approximately 10 to 20 micrograms of LSD (lysergic acid diethylamide) or 0.1 to 0.3 grams of dried psilocybin mushrooms, doses intended to be below the threshold of conscious psychedelic effects. Users follow various protocols: one day on, two days off (the Fadiman protocol); four days on, three days off; or less structured regimens. The intended goal is not a psychedelic experience but rather subtle cognitive or emotional enhancement during normal daily activities.
This is fundamentally different from the therapeutic psychedelic paradigm being studied in clinical trials (psilocybin-assisted therapy for treatment-resistant depression, PTSD, etc.), which uses full doses in controlled settings with trained therapists. Therapeutic psychedelic research has produced genuinely promising results, but these findings do not validate microdosing. The mechanisms are likely different: full-dose psychedelic therapy appears to work through profound state changes in neural connectivity (the “mystical experience” correlate), while microdosing at sub-perceptual levels cannot produce these state changes by definition.
What the Controlled Studies Show
The critical question for microdosing is whether its reported benefits exceed placebo effects. Several rigorous studies have addressed this. The Imperial College London self-blinding study (Szigeti et al., 2021) asked microdosers to create their own placebo-controlled experiment using opaque capsules. Over four weeks, there was no significant difference between microdose and placebo groups on measures of cognitive function, wellbeing, or creativity, although both groups reported improvements, confirming strong expectancy (placebo) effects.
The University of Chicago laboratory study (Family et al., 2020) administered controlled doses of LSD (6.5, 13, and 26 micrograms) in a double-blind design. Low doses of LSD altered some subjective drug effects and time perception but did not improve mood, cognition, or creativity compared to placebo. A subsequent study from Maastricht University found that very low doses of psilocybin (0.5 mg) did not improve creativity or cognitive flexibility on standardised tests, despite participants reporting subjective improvements. These findings collectively suggest that the perceived benefits of microdosing are substantially driven by expectancy rather than pharmacological effects.
Microdosing Claims vs Scientific Evidence
| Claimed Benefit | Self-Report Survey Findings | Controlled Trial Findings |
|---|---|---|
| Improved creativity | Widely reported; subjective improvement | No significant improvement over placebo on standardised measures |
| Enhanced mood | Frequently reported; reduced depression scores | Improvement not distinguishable from placebo in blinded studies |
| Better focus and productivity | Commonly reported; subjective cognitive enhancement | No objective cognitive improvement demonstrated |
| Reduced anxiety | Some report improvement; some report worsening | Insufficient controlled data; some reports of increased anxiety |
| Increased energy | Reported by a subset of users | Minimal stimulant effects noted at low LSD doses but no sustained benefit |
Real Risks of Microdosing
While the benefits of microdosing remain unproven, several risks are pharmacologically grounded. The most concerning is cardiac valvulopathy from chronic 5-HT2B receptor agonism. Both psilocin (the active metabolite of psilocybin) and LSD activate the serotonin 5-HT2B receptor on cardiac valve interstitial cells. Chronic 5-HT2B activation is the established mechanism behind valvular heart disease caused by fenfluramine (Fen-Phen), ergotamine, and pergolide. While occasional psychedelic use is unlikely to cause valvular pathology, the chronic, repeated dosing schedule of microdosing protocols raises a theoretical concern that has not been adequately studied.
Drug interactions represent another genuine risk. Both psilocybin and LSD are serotonergic, and combining them with SSRIs, SNRIs, MAOIs, lithium, or other serotonergic medications can produce unpredictable effects ranging from reduced efficacy to serotonin syndrome. The interaction with lithium is particularly concerning: case reports describe seizures when psychedelics are combined with lithium. People who discontinue psychiatric medications to microdose risk relapse of their underlying condition, which may be far more dangerous than the condition they were using microdosing to treat.
Unregulated product quality is a practical risk. Outside of clinical trials, microdosers obtain their substances from unregulated sources. LSD doses can vary significantly between tabs or drops, making consistent “sub-perceptual” dosing difficult. Psilocybin mushroom potency varies substantially by species, growing conditions, and individual mushroom, meaning the same weight of mushrooms can deliver significantly different psilocybin doses. Some users may inadvertently take perceptual doses, which can impair functioning during work, driving, or caregiving.
Clinical insight: At Phuket Island Rehab, we assess microdosing history as part of a comprehensive substance use evaluation. The clinical concern is not microdosing itself but the pattern we occasionally see: a patient discontinues evidence-based psychiatric medication in favour of microdosing, experiences symptom relapse, and then escalates their psychedelic use or adds other substances to compensate. The microdosing becomes part of a broader pattern of unsupervised self-medication rather than a standalone practice.
When Substance Use Has Become More Than Occasional
Classical psychedelics (psilocybin, LSD, DMT) produce rapid tolerance (tachyphylaxis) that makes physical dependence and a classical addiction syndrome unlikely. However, psychological dependence on the microdosing practice can develop, particularly when it serves as a coping strategy for underlying mental health conditions. If you find that you are unable to discontinue microdosing without significant anxiety, if you have replaced prescribed medications with psychedelics without clinical guidance, or if your substance use has expanded beyond microdosing to include other psychoactive substances, these are patterns that warrant professional assessment.
For individuals whose microdosing is part of a broader pattern of polysubstance use or self-medication, comprehensive assessment and treatment at Phuket Island Rehab can address the full clinical picture, ensuring that underlying mental health conditions receive evidence-based treatment and that substance use patterns are evaluated in their entirety.
Summary
Microdosing psychedelics is a practice driven more by cultural enthusiasm than by current scientific evidence. Controlled studies have not demonstrated benefits beyond placebo for creativity, mood, or cognitive enhancement. Meanwhile, real risks exist including potential cardiac valvulopathy from chronic 5-HT2B activation, dangerous interactions with psychiatric medications, and the hazards of replacing evidence-based treatment with unregulated substances. The promising research on therapeutic psychedelic use involves full doses in controlled clinical settings, not sub-perceptual doses self-administered at home.
“The distinction between evidence-based psychedelic research and the microdosing movement is important and often overlooked,” says Dr. Ponlawat Pitsuwan. “Clinical trials of psilocybin-assisted therapy are conducted with pharmaceutical-grade compounds, careful screening, professional therapeutic support, and rigorous monitoring. Microdosing as practised by the general public involves none of these safeguards. Until controlled trials demonstrate that microdosing produces benefits beyond placebo effects and that the chronic dosing schedule is safe for the cardiovascular system, recommending it as a mental health intervention is premature.”
Frequently Asked Questions
Does microdosing actually work?
Current evidence from double-blind, placebo-controlled studies suggests that most reported benefits of microdosing are attributable to placebo and expectancy effects rather than pharmacological action. Self-reported benefits in unblinded surveys are substantial, but when participants do not know whether they received a microdose or a placebo, the differences disappear or become minimal. This does not mean microdosing has zero pharmacological effect, but it does mean the effect size, if any, is small enough that current studies cannot distinguish it from placebo.
Is microdosing safe?
The acute safety profile of a single sub-perceptual dose is likely favourable in healthy individuals with no psychiatric vulnerabilities and no concurrent serotonergic medications. However, the long-term safety of chronic, repeated dosing has not been established. The specific concern about 5-HT2B-mediated cardiac valvulopathy with chronic use has not been adequately studied. Drug interactions with psychiatric medications, unpredictable dosing from unregulated sources, and the risk of inadvertently taking perceptual doses are additional practical safety concerns.
Can microdosing replace antidepressants?
No. Current evidence does not support microdosing as a replacement for evidence-based psychiatric medication. SSRIs and SNRIs have extensive clinical trial data demonstrating efficacy for major depression and anxiety disorders. Microdosing has no such data. Discontinuing prescribed medication in favour of microdosing risks relapse of the underlying condition, which can be clinically dangerous, particularly for conditions like major depression with suicidal features or bipolar disorder.
What is the cardiac risk from microdosing?
Both psilocin and LSD activate the 5-HT2B receptor on cardiac valve interstitial cells. Chronic 5-HT2B agonism is the established mechanism behind the cardiac valvulopathy caused by drugs like fenfluramine (Fen-Phen). While no cases of microdosing-associated valvulopathy have been reported in the literature, the chronic dosing schedule of microdosing protocols theoretically creates the conditions for this risk. The absence of reported cases reflects the absence of systematic study rather than confirmed safety.
Is microdosing legal?
In most jurisdictions, psilocybin and LSD are Schedule I controlled substances, making any possession or use illegal regardless of dose. Some jurisdictions have moved toward decriminalisation (Oregon, several US cities, the Netherlands for psilocybin truffles), but decriminalisation is not the same as legalisation or regulation. In most countries, microdosing remains illegal, and possession can carry significant criminal penalties. The illegality also means there is no quality control, standardisation, or regulatory oversight of products used for microdosing.
Can microdosing trigger a psychotic episode?
At truly sub-perceptual doses, the risk of acute psychosis is very low. However, the inconsistency of unregulated dosing means users may inadvertently take a perceptual or full dose, which does carry psychosis risk, particularly in individuals with family histories of psychotic disorders or bipolar disorder. Additionally, chronic serotonergic stimulation, even at low levels, could theoretically exacerbate vulnerability to psychotic episodes in predisposed individuals, though this has not been systematically studied in the microdosing context.
Sources
Szigeti B, et al. “Self-blinding citizen science to explore psychedelic microdosing.” eLife. 2021;10:e62878.
National Institute on Drug Abuse (NIDA). “Psychedelic and Dissociative Drugs.” drugabuse.gov
Johnson MW, et al. “Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.” Pharmacology and Therapeutics. 2019;197:83-102.
Microdosing · Psilocybin · Psilocin · LSD · 5-HT2A receptor · 5-HT2B receptor · Cardiac valvulopathy · Serotonin syndrome · Placebo effect · Expectancy bias · Fadiman protocol · Tachyphylaxis · SSRIs · Schedule I · Psilocybin-assisted therapy · Phuket Island Rehab